anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objectives: To quantify the prevalence of drug-resistant Gram-negative pathogens on admission to a neonatal intensive care unit and during subsequent days of hospital stay. To quantify rates of patient-to-patient transmission for key organisms, to characterize how patient antibiotic use impacts on the ward-level dynamics of such organisms.

Methods: All infants admitted to the unit over a period of one year for whom the parent/guardian gives informed consent will be included. In addition to routine demographic and clinical data for included patients, full patient-level data on antibiotic use within the ward will also be recorded. Carriage of resistant Gram-negative organisms will be determined though rectal swabs, tracheal aspirates (for ventilated patients) and stool samples taken on admission and at twice weekly intervals. Antibiotic-resistant Gram-negative bacteria will be cultured and their resistant patterns determined. Selected environmental surfaces will also be sampled to detect contamination with such organisms. For the most important organisms (Acinetobacter spp. and Klebsiella spp.) whole genome sequencing will be used in conjunction with Bayesian data augmentation techniques to determine transmission pathways and the impact of antibiotic use on the transmission and persistence of such organisms within the hospital ward.
PROBLEM TO BE SOLVED: To obtain a skin lotion composition giving a natural finished skin by masking the dark ring under the eye and the dark skin and exhibiting excellent effect for gradually improving the dark ring and dark skin by formulating a specific titanium mica and a blood flow improving agent. SOLUTION: The objective composition is produced by formulating (A) one or more kinds of titanium mica coated with interferential iron oxide film and having a spectral reflection characteristics giving an interference light having a hue (H) belonging to P, RP, R, YR and Y regions (purple to yellow) in Munsell color system and (B) one or more kinds of blood flow improving agent. The component A is e.g. titanium mica coated with yellow iron oxide or red oxide and its content in the composition is preferably 0.1-10.0 wt.%. The component B is e.g. a vitamin E derivative, a nicotinic acid derivative and extract of Swertia japonica and its content in the composition is preferably 0.01-2.0 wt.%.
Microplastics (MPs) and nanoplastics (NPs) are now widely recognized as a ubiquitous and pervasive environmental pollutant with important consequences for aquatic fauna in particular; however, little is known regarding their potential effects on interactions between hosts and their parasites or pathogens. We conducted a literature survey of published studies that have conducted empirical investigations of MP and NP influences on infectious disease dynamics to summarize the current state of knowledge. In addition, we examined the effects of microbead (MB) ingestion on the longevity of freshwater snails (Stagnicola elodes) infected by the trematode Plagiorchis sp., along with their production of infectious stages (cercariae), with a 3-week lab study during which snails were fed food cubes containing either 0, 10 or 100 polyethylene MBs sized 106-125 μm. We found 22 studies that considered MP and NP influences on host resistance or tolerance-20 of these focused on aquatic systems, but there was no clear pattern in terms of host effects. In our lab study, MB diet had marginal or few effects on snail growth and mortality, but snails exhibited a significant non-monotonic response with respect to cercariae production as this was greatest in those fed the high-MB diet. Both our literature summary and experimental study indicate that MPs and NPs can have complex and unpredictable effects on infectious disease dynamics, with an urgent need for more investigations that examine how plastics can affect aquatic fauna through direct and indirect means.
The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. A gene therapy DNA vector based on the VTvaf17 gene therapy DNA vector is proposed that carries a target gene selected from the group of SHH, CTNNB1, NOG, WNT7A genes for the treatment of diseases characterized by impaired tissue regeneration, wound healing, growth, pigmentation and hair coloring, formation and maturation of hair follicles, processes of differentiation and growth of cells, leading to a decrease in the activity of hair follicles, including with allopecia, autoimmune diseases, hereditary and acquired pathological conditions thawing, and for accelerated healing of wounds, restoration of the hairline and the prevention and inhibition of alopecia. Moreover, the gene therapy DNA vector VTvafl7-SHH, or VTvaf 17 -CTNNB 1, or VTvaf17-NOG, or VTvaf17-WNT7A has the nucleotide sequence of SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4, respectively. Also provided are a method of producing said vector, the use of a vector, a strain of Escherichia coli carrying said vector, as well as a method of industrial production of said vector.
OBJECTIVE: To investigate the auditory perception of roughness and breathiness by dysphonic women.
METHODS: Twenty-two dysphonic native Brazilian Portuguese women participated in this research. All participants underwent audiological evaluation and laryngeal examination to confirm the diagnosis. During the tests, they recorded the sustained vowel /Ɛ/. A speech-language pathologist performed the auditory-perceptual judgment of voice quality for these vocal samples, categorizing the general degree of vocal deviation (mild, moderate, and severe degree) and the predominant type of deviation (roughness or breathiness). Thirty-two (32) stimuli were selected from a voice database, including twenty-four (24) dysphonic voice samples and eight (8) voice samples from vocally healthy women. The authors conducted five perception experiments, being three categorization tasks (normal vs. deviated, breathy vs. nonbreathy, rough vs. nonrough) and two tasks for discriminating the degree of deviation (roughness degree and breathiness degree).
RESULTS: The experiments showed a difference between the answers for presence/absence of deviation, presence/absence of breathiness, and presence/absence of roughness in the stimuli, and a difference in the proportion of similar answers of dysphonic women (P < 0.001) regarding the identification of the deviation. Participants classified a large part of the deviated (57.9%), breathy (63.13%), and rough (65.31%) voices as normal. The degree of vocal deviation (P = 0.008) and the degree of roughness in the stimuli correlated positively with the proportion of similar answers of the participants. As for the discrimination of breathiness degrees, less deviated (normal and mild) voices were less discriminated, and more deviated (moderate and severe) voices were better discriminated. Regarding the discrimination of roughness degrees, only the voices with severe deviations showed good discrimination.
CONCLUSION: Dysphonic women had a high rate of not similar answers in the identification of normal and deviated voices. They identified more than half of the deviated voices as normal. Samples with more severe deviations were proportionally more identified as deviated by the participants. The greater the vocal deviation of the participants' voices, the smallest the number of similar answers. Participants had a high rate of not similar answers in the identification of normal and breathy voices. Dysphonic women show less ability to perceive mildly and moderately breathy voices in the breathy category. Participants had a high rate of similar answers in the identification of normal and rough voices. Dysphonic women show less ability to perceive mildly and moderately breathy voices in the breathy category. Participants show less ability to perceive only mildly roughness voices with similar responses. Dysphonic women could discriminate between voices with adjacent degrees of roughness but had a low percentage of similar answers for discrimination between voices with adjacent degrees of breathiness.
Participants will receive ME-401 dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose R-CHOP. ME-401 (60 mg) will be given on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle with standard dose R-CHOP x 6 cycles.
Hypertension affects 20% to 25% of adult population. Most patients are diagnosed as having essential or primary hypertension. Up to 10% to 15 % have an identifiable cause and many of those have an adrenal basis \[Miroslava H. et al., 2002\]. The tissue kallikrein-kinin (KKS) and renin-angiotension-aldosterone system (RAAS) had been implicated in regulating blood pressure and electrolyte homeostasis. Recent studies in humans indicate that the vasodilator tissue KKS, the counterpart of the tissue RAAS, is also expressed in the adrenal gland. The adrenal gland regulates sodium and water excretion and reabsorption through the release of aldosterone and corticosterone. Previous study reveals an anatomical linkage between the tissue KKS and sodium and water metabolism. Both of the KKS and RAAS may work coordinately to regulate salt metabolism, local blood flow. In contrast, although many investigators have supported the notion that Ang II and BK physiologically antagonize each other's effects on blood pressure, there are many instances where the two peptides exert common actions. For example, the Bradykinin also stimulates aldosterone release from adrenocortical cells through B2 receptors. Furthermore, the AT1 receptor and the bradykinin (B2) receptor form stable heterodimers, the two major signaling proteins triggered by AT1. In vitro studies (Margolius 1995) have shown that kallikrein acts as a prorenin-activating enzyme, and that tissue kallikrein can generate angiotensin II.

However, the interactions between both systems are complex and not always simply antagonistic. The interactions of the two systems on aldosterone secretion are not examined Thus, we conducted this study to elucidate, first, whether some alterations in components of the kallikrein-kinin system could do effect on aldosterone secretion.

Our study provides evidence that bradykinin contributes substantially to the aldosterone secretion with or without the effects of angiotensin. The data also could confirm whether ATR2-Bradykinin-B2-aldosterone really works. We want to realize the expression of angiotensin and bradykinin in the adrenal gland and hypertension related to these systems.

Previous study has showed the post captopril plasma aldosterone concentration (PAC)/ plasma rennin activity (PRA) ration (ARR) was a reliable method for diagnosis of primary aldosteronism (PA). The ARR change by angiotensin II receptor blockade was reported to be significantly higher than that by ACE inhibitor. This study assessed whether angiotensin II receptor blockade offers any additional advantage in the diagnosis of PA. Clinically we evaluated the sensitivity and specificity of captopril (angiotensin-converting enzyme inhibition) and losartan (angiotensin II type 1 receptor blocker) test in PA patient. This interaction mechanism, in term, could further explain the interaction of KKS and RAAS.
Calcifediol, USP, the active ingredient in RAYALDEE, is synthetically manufactured as calcifediol monohydrate. Calcifediol is also known as calcidiol, 25-hydroxycholecalciferol or 25-hydroxyvitamin D3.

Calcifediol monohydrate is a white crystalline powder, has a calculated molecular weight of 418.65 and is soluble in alcohol and fatty oils but practically insoluble in water. Chemically, calcifediol monohydrate is (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol monohydrate and its structural formula is:

RAYALDEE is formulated as extended-release capsules containing 30 mcg of calcifediol.

RAYALDEE is available as soft capsules or two-piece banded hard capsules containing 30 mcg of calcifediol for oral administration. Each capsule contains the following excipients: butylated hydroxytoluene, dehydrated alcohol, hypromellose, lauroyl polyoxylglycerides, mineral oil, monoglycerides and diglycerides, and paraffin. The soft capsule shells contain carrageenan, FD&C Blue #1, modified starch, purified water, sodium phosphate dibasic, sorbitol sorbitan solution, and titanium dioxide. Medium chain triglyceride (fractionated coconut) oil is used as a lubricant during manufacture, and trace amounts may be present in the final formulation. The hard capsule shells contain gellan gum, hypromellose, and titanium dioxide.
PURPOSE:To provide a plasmin inhibitor containing a sulfate of an oligosaccharide composed of only glucose or a homopolysaccharide as the active component, exhibiting a high specificity to plasmin, having a higher effect and reduced in side-effects. CONSTITUTION:This plasmin inhibitor contains a sulfate selected from a group of sulfates of beta(1+3) glucan represented by formula I [(n) is 2 to 694] and having a structure in which glucose residues are bonded through a beta(1 6) glucoside linkage and oligosaccharides derived from the above-mentioned glucan and represented by formulae II, III or IV as the active component. The sulfation decree of the sulfates of the glucan and the oligosaccharides is controlled to 0.5 to 25wt.% on sulfur base. This inhibitor is administated preferably by intravenous drip and oral administration or injection is also effective. In the case of oral administration, this inhibitor is administrated in an amount of 0.1 to 20mg/kg.day per an adult in one to six times. Since it is specific to plasmin, it is worthier as an experimental reagent in comparison with the conventional protease inhibitor. The above-mentioned sulfates are low-toxic and this plasmin inhibitor is very worth as a medical drug.
Many HIV-infected women outside the United States enroll in clinical trials that provide them antiretroviral therapy (ART) to prevent mother-to-child transmission of HIV. However, data are limited on the safety, toxicity, and adverse effects that maternal ART may have on infants born to HIV-infected women. This study will monitor the adverse effects and potential benefits of maternal ART on these infants.

No antiretrovirals will be given in this study. This study will last 18 months. Infants will be enrolled in the study within 48 hours of birth. There will be 6 study visits starting at study entry and every 6 weeks thereafter. Infants will undergo blood and urine collection, and medical history assessments will occur at every visit. Mothers will also be evaluated at these visits.
Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room. The physician will follow their own institutional weaning protocols.
PURPOSE: Benign skin lesions in zygomatic-infraorbital regions severely influence pediatric patients' appearance as well as mental health. Treatments are difficult for the high requirements of patients' guardians in both function and aesthetics. The present study aims to introduce a surgical method, Expanded Multi-Lobe Cervicofacial Flap, which combines the advantages of the classical cervicofacial advancement rotation flap and the tissue expansion technique.
METHODS: A total of 21 pediatric patients were enrolled. The treatment process included 2 stages: implantation of the skin tissue expander and flap transfer. The excessive skin created by tissue expansion extended the coverage area of the multi-lobe flap.
RESULTS: In this retrospective study, follow-up periods were all more than 12 months (20.8 ± 6.7). In the last follow-ups, the flaps were all in good condition, and No facial organ displacement was observed. The patients' guardians were satisfied with the outcomes.
CONCLUSIONS: Using the expanded multi-lobe cervicofacial flap for the zygomatic-infraorbital benign skin lesion repair is effective, and this method is especially applicable to the pediatric population.
A broad range of tumors have been shown to contain significant numbers of hypoxic cells and hypoxia has been shown to be associated with a poor prognosis and an increase in resistance to chemotherapy and radiotherapy (Brizel 1997, Vaupel 2007, Shannon 2003).

It is likely that an agent that could effectively target hypoxic regions in tumors would improve efficacy when combined with standard chemotherapy or radiotherapy. TH-302 is activated at lower oxygen concentrations than other bioreductive prodrugs (Duan 2008) and tirapazamine, a hypoxic cytotoxin that has been extensively studied in both preclinical and clinical studies. This should result in an improved therapeutic ratio (tumor vs normal tissue toxicity) as compared with other bioreductive agents. Because TH-302 is expected to be minimally toxic to aerobic cancer cells, optimal efficacy would be expected when TH-302 is combined with treatments that are most effective under aerobic conditions such as radiotherapy and cytotoxic chemotherapy. Preclinical data have shown at least additive efficacy when TH-302 is combined with chemotherapy. In order to minimize the risk of additive toxicity, TH-302 is not being evaluated in combination with alkylating agents. The study will enroll subjects with advanced soft tissue sarcoma. These tumors have evidence supporting the presence of hypoxia based on pO2 histography, F-MISO and gene expression profiling (Vaupel 2007, Francis 2007, Rajendran 2003).
Nonalcoholic steatohepatitis (NASH) is a metabolism-associated fatty liver disease with accumulated mitochondrial stress, and targeting mitochondrial function is a potential therapy. The mitochondrial genome-encoded bioactive peptide MOTS-c plays broad physiological roles, but its effectiveness and direct targets in NASH treatment are still unclear. Here, we show that long-term preventive and short-term therapeutic effects of MOTS-c treatments alleviate NASH-diet-induced liver steatosis, cellular apoptosis, inflammation, and fibrosis. Mitochondrial oxidative capacity and metabolites profiling analysis show that MOTS-c significantly reverses NASH-induced mitochondrial metabolic deficiency. Moreover, we identify that MOTS-c directly interacts with the BH3 domain of antiapoptotic B cell lymphoma-2 (Bcl-2), increases Bcl-2 protein stability, and suppresses Bcl-2 ubiquitination. By using a Bcl-2 inhibitor or adeno-associated virus (AAV)-mediated Bcl-2 knockdown, we further confirm that MOTS-c improves NASH-induced mitochondrial dysfunction, inflammation, and fibrosis, which are dependent on Bcl-2 function. Therefore, our findings show that MOTS-c is a potential therapeutic agent to inhibit the progression of NASH.
In response to inserting a Continuous Glucose Monitoring (CGM) sensor into the skin of a user, the CGM system compares the identifier of the sensor to any previously stored identifiers of previously inserted sensors. If the identifier does not match a previously stored identifier, indicating a newly inserted sensor, the identifier and timestamp are stored and the CGM can start. Upon removal of the sensor, a removal timestamp is stored. If the identifier of the inserted sensor matches the previously stored identifier, indicating a reinserted sensor, the reinsertion time is obtained and the elapsed removal time is checked to determine if it exceeds the maximum removal time limit. If it exceeds the maximum removal time limit, the CGM pauses. If it does not exceed the maximum removal time limit, the CGM can continue with the reinserted sensor. Methods of tracking the insertion time and removal time of a CGM sensor are also provided, as well as other aspects.
Dry cupping will provided to the subjects thrice a week for 4 weeks in the dry cupping therapy group, a plastic cupping bell will be used. Cups will applied to the painful site for 10 minutes in each session. A manual hand pump was used to create the vacuum for suction. The intensity of the vacuum will based on subject tolerance.
The investigators are planning to perform a retrospective study analyzing cases of emphysematous pyelonephritis from a single tertiary care institution in the north of Mexico in the period of 2011-2021. The diagnosis of emphysematous pyelonephritis is confirmed by computed tomography. Demographic, clinical, biochemical, therapeutic management, and outcomes will be collected. Variables will be analyzed to determine factors associated with admission to intensive care unit and mortality. Urine cultures will be analyzed and drug resistance profile will be determined using microdilution plate. Clinical and demographic characteristics will be analyzed using Chi square test for categorical variables, and T-test for numerical variables. Statistical significance is set at p\<0.05. Statistical analysis will be performed with the SPSS software version 20.0.
Androgenetic alopecia seriously affects the physical and mental health of patients. The main clinical therapeutic agent, minoxidil tincture, is challenged by solvent irritation and dose-dependent side effects. Our recent work has identified a biosafety natural product, cedrol, that is synergistic in combination with minoxidil, thereby improving medication safety by substantially reducing the clinical dose of minoxidil. In addition, ccross-linked CD-MOF were designed as carriers for hair follicle delivery, and γ-CD in the carriers was cross-linked by diphenyl carbonate with covalent bonds to protect the CD-MOF from rapid disintegration in an aqueous environment. This improved nanocarrier has a drug loading of 25%, whereas nanocarriers increased drug delivery to the hair follicles through ratchet effect, and increased human dermal papilla cells uptake of drugs via endocytosis pathways mainly mediated by lattice proteins, energy-dependent active transport, and lipid raft-dependent, thus improved cell viability, proliferation, and migration, followed by significantly enhancing the anti-androgenetic alopecia effect, with cedrol focusing on inhibiting 5α-reductase and activating Shh/Gli pathway, and minoxidil, which up-regulated VEGF, down-regulated TGF-β, and activated ERK/AKT pathway. This drug combination provides a new therapeutic strategy for androgenetic alopecia, while the newly developed cross-linked CD-MOF has been shown to serve as a promising follicular delivery vehicle.
The invention relates to a bovine colostrum immunoglobulin G preparation for treating diarrhea and a preparation method thereof. The bovine colostrum immunoglobulin G preparation mainly comprises, by weight, 5%-30% of bovine colostrum IgG, 1.0%-8% of a buffer and 65%-90% of a protective agent. The colostrum IgG has purity of 90% or more. The preparation method of the colostrum immunoglobulin G preparation for treating diarrhea comprises 1) after the high purity IgG solution is obtained through purification, adding the buffer into the IgG solution, adjusting the pH of the solution to 7 through an alkali solution, and carrying out vacuum concentration at a temperature of 40 DEG C to obtain a concentrate of which the volume is 30% to 50% of the original volume, and 2) adding the protective agent into the concentrate and carrying out drying and spraying to obtain microcapsule powder. The preparation is not decomposed by gastric acid and digestive enzymes, and is particularly suitable for treatment on rotavirus-induced diarrhea. The preparation method has the advantages of simple processes and low cost and is suitable for large-scale production.